Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
Mylan N.V.
IndexS&P 500 P/E164.48 EPS (ttm)0.11 Insider Own0.20% Shs Outstand516.00M Perf Week0.58%
Market Cap8.91B Forward P/E3.83 EPS next Y4.51 Insider Trans11.67% Shs Float507.62M Perf Month-8.28%
Income54.30M PEG37.38 EPS next Q1.27 Inst Own87.90% Short Float4.54% Perf Quarter-1.93%
Sales11.39B P/S0.78 EPS this Y-57.40% Inst Trans-0.53% Short Ratio3.93 Perf Half Y-14.55%
Book/sh22.22 P/B0.78 EPS next Y4.98% ROA0.10% Target Price25.81 Perf Year-51.95%
Cash/sh- P/C- EPS next 5Y4.40% ROE0.40% 52W Range16.63 - 36.46 Perf YTD-36.97%
Dividend- P/FCF5.95 EPS past 5Y-16.70% ROI3.50% 52W High-52.63% Beta1.73
Dividend %- Quick Ratio0.80 Sales past 5Y10.60% Gross Margin39.40% 52W Low3.85% ATR0.67
Employees35000 Current Ratio1.40 Sales Q/Q3.50% Oper. Margin5.90% RSI (14)37.11 Volatility3.31% 3.74%
OptionableYes Debt/Eq1.14 EPS Q/Q22.20% Profit Margin0.40% Rel Volume1.23 Prev Close17.53
ShortableYes LT Debt/Eq1.09 EarningsNov 05 BMO Payout0.00% Avg Volume5.87M Price17.27
Recom2.10 SMA20-6.34% SMA50-11.03% SMA200-22.40% Volume7,223,192 Change-1.48%
Nov-07-19Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-05-19Downgrade CFRA Hold → Sell
Jul-19-19Initiated Wolfe Research Outperform
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Nov-13-19 02:48PM  Edited Transcript of MYL earnings conference call or presentation 5-Nov-19 3:00pm GMT Thomson Reuters StreetEvents
08:00AM  Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks Zacks
Nov-12-19 12:15PM  Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination PR Newswire
Nov-08-19 02:11PM  7 Large-Cap Stocks to Give a Wide Berth InvestorPlace
09:59AM  Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase Zacks
09:38AM  With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback InvestorPlace
Nov-07-19 02:30PM  7 Stocks the Vanguard Health Care Fund Keeps Buying
10:56AM  EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Mylan N.V. GlobeNewswire
Nov-06-19 12:37PM  Teva earnings preview: Opioid suits are key MarketWatch
11:19AM  Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates Zacks
09:16AM  UPDATE 3-U.S. SEC enforcement activity hits second-highest level ever in 2019 Reuters
Nov-05-19 04:07PM  This Pharma Giant Just Triggered A Sell Rule On Its Mixed Third Quarter Investor's Business Daily -9.88%
01:12PM  Coury on Mylan merger: 'We're moving the company to something quite different" American City Business Journals
12:37PM  Mylan shares slide 5.5% as CFRA downgrades to sell from hold MarketWatch
11:45AM  Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates Zacks
11:41AM  Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss Zacks
10:59AM  Mylan Q3 Non-GAAP EPS Beats Street Estimate; Drugmaker Narrows Guidance Range Benzinga
09:27AM  Mylan Doles Out the Right Prescription for Investors
09:13AM  US STOCKS-Wall St set to open higher as trade optimism builds Reuters
08:58AM  Euphoric investors trigger alarm bells over stock market rally MarketWatch
08:25AM  Mylan (MYL) Q3 Earnings Surpass Estimates Zacks
07:43AM  UPDATE: Mylan tops profit estimates and offers upbeat guidance MarketWatch
07:27AM  UPDATE 3-Mylan shares slide after warning of hit to revenue Reuters
07:07AM  Mylan tops profit estimates as newer drugs spur North America growth Reuters
07:07AM  Mylan shares slide after warning of hit to revenue Reuters
07:00AM  Mylan Reports Third Quarter 2019 Results and Updates 2019 Guidance PR Newswire
06:30AM  Mylan Beats Earnings Estimates With Shares in Recovery Mode
04:35AM  [video]Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast
02:03AM  Mylan Earnings Beat, Revenue Misses In Q3
Nov-04-19 01:10PM  Mylan's Q3 Earnings Preview Benzinga
12:27PM  Day Ahead: Top 3 Things to Watch
11:23AM  Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More Zacks
08:31AM  Should You Buy Mylan (MYL) Ahead of Earnings? Zacks
Oct-31-19 11:27AM  Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View Zacks
Oct-30-19 12:17PM  Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily
11:46AM  Mylan (MYL) to Report Q3 Earnings: What's in the Offing? Zacks
Oct-29-19 12:41PM  Pfizer to become smaller, science-based company following Mylan deal American City Business Journals
10:33AM  Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy? Zacks
10:03AM  Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View Zacks
08:08AM  Pfizer Stock Is Getting a Lift Because Things Are a Lot Better Than Wall Street Thought
01:55AM  Pfizer and Merck raise guidance on strong China growth Financial Times
Oct-28-19 10:24AM  RPT-UPDATE 1-Allergan settles Alzheimer's therapy lawsuit for $750 million Reuters
08:37AM  UPDATE 2-New tuberculosis treatment for developing countries to cost $1,040 Reuters
08:00AM  Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS) GlobeNewswire
07:18AM  CORRECTED-New tuberculosis treatment for developing countries to cost $1,040 Reuters
Oct-25-19 06:33PM  Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance PR Newswire
10:32AM  5 Undervalued Stocks to Buy InvestorPlace
Oct-24-19 11:24AM  Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? Zacks
10:16AM  Pfizer (PFE) to Report Q3 Earnings: What's in the Cards? Zacks
07:30AM  Mylan to Release Third Quarter 2019 Financial Results on Nov. 5, 2019 PR Newswire
Oct-21-19 04:00PM  Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting PR Newswire
Oct-17-19 03:38PM  Why Health Care Stocks Can Rebound Despite 2020 Election Turmoil Investopedia
Oct-12-19 02:56PM  Is Mylan N.V. (MYL) A Good Stock To Buy? Insider Monkey
Oct-10-19 10:10AM  Why the Earnings Surprise Streak Could Continue for Mylan (MYL) Zacks
Oct-07-19 10:25AM  Theravance Pipeline Strong, Dependence on Yupelri a Concern Zacks
Oct-01-19 06:56PM  As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets
Sep-30-19 05:45PM  Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen Zacks
Sep-27-19 05:03PM  Mylan Misled Investors Over EpiPen Pricing Probe, SEC Says Bloomberg
04:35PM  Mylan Stock Dives On $30 Million Settlement In EpiPen Scandal Investor's Business Daily
10:41AM  Mylan will pay $30M to settle charges related to EpiPen probe American City Business Journals
10:37AM  SEC fines Mylan $30 million for Epipen disclosure failure MarketWatch
10:25AM  Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission PR Newswire
10:16AM  Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe Reuters
08:32AM  Mylan to Pay $30M to Settle SEC Lawsuit Related to EpiPen Misclassification
Sep-25-19 04:37PM  How This IBD Stock Of The Day Is Rattling Medical Giants Amgen, Mylan Investor's Business Daily
Sep-24-19 06:34AM  LabCentral co-founder issues call to action' to biotechs on drug pricing American City Business Journals
Sep-20-19 10:50PM  The Opioid Crisis Hits Home for Investors
Sep-19-19 11:32AM  J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use Zacks
09:10AM  Pfizer Is Spinning Off Upjohn. Whats Left Will Be No Bargain, Analyst Says
Sep-17-19 09:30AM  Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer PR Newswire
Sep-11-19 03:50PM  Leaner Pfizer Positioned to Boost R&D Output
Sep-06-19 11:57AM  Pfizer is a Top Drugmaker: Is it the Right Time to Buy It? Zacks
Sep-04-19 07:00AM  Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019 GlobeNewswire
Sep-03-19 11:00AM  Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks
06:45AM  The 3 Worst Health Care Stocks So Far This Year
Aug-30-19 08:22AM  3 Big Stock Charts for Friday: Mylan, Newell and Home Depot InvestorPlace
Aug-29-19 05:06PM  U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta Reuters
04:22PM  Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly Drug Investor's Business Daily
09:06AM  Forget Pfizer, Add These Big Drugmakers to Your Portfolio Zacks
Aug-28-19 09:30AM  Mylan (MYL) Down 12.9% Since Last Earnings Report: Can It Rebound? Zacks
Aug-27-19 11:01AM  4 Biotech Stocks to Buy That Are on the Move InvestorPlace
Aug-26-19 01:17PM  Historic Bear Signal Spells Bad News for Mylan Stock Schaeffer's Investment Research
Aug-22-19 02:39PM  Novo Nordisk Suing Mylan Over Generic Victoza Drug InvestorPlace
03:09AM  Denmark's Novo Nordisk files lawsuit against Mylan over patent Reuters
Aug-21-19 11:04AM  Teva Launches Generic Version of Mylan's EpiPen for KIds Zacks
Aug-20-19 08:23AM  Teva to launch generic version of EpiPen for young children Reuters
05:31AM  [video]Teva's Generic EpiPen Jr Is Now Available for $300
Aug-19-19 05:15AM  The 6 Worst Health-Care Stocks So Far This Month
Aug-15-19 11:54AM  10 Cheap Dividend Stocks to Load Up On InvestorPlace
09:48AM  Drug Stocks Sank After 2 Members of Congress Reopened a Price-Fixing Inquiry
09:30AM  Company News For Aug 15, 2019 Zacks
Aug-14-19 01:56PM  Lawmakers want more answers from Mylan over drug pricing probe American City Business Journals -8.52%
01:24PM  UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis Reuters
12:57PM  U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis Reuters
12:16PM  Generic-Drug Giants Accused of Blocking Congressional Probe Bloomberg
09:50AM  Should Value Investors Pick Mylan N.V. (MYL) Stock? Zacks
07:23AM  UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe Reuters
06:28AM  U.S. lawmakers push Mylan, Teva over drug pricing probe -statement Reuters
Aug-12-19 01:57PM  Pfizer's stock sinks again, toward 14-month low to pace 'Dow's' losers MarketWatch
09:44AM  Amgen Wins Enbrel U.S. Patent Litigation Against Novartis Zacks
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HIGGINS MELINA EDirectorAug 15Buy17.6820,000353,54833,120Aug 19 07:29 PM
Vollebregt Sjoerd SDirectorAug 14Buy18.8124,000451,43942,258Aug 15 06:30 PM
Vollebregt Sjoerd SDirectorAug 13Buy19.1110,000191,10018,258Aug 15 06:30 PM
COURY ROBERT JDirectorAug 02Buy20.0649,8591,000,012947,194Aug 05 08:00 AM
MARK RICHARD ADirectorJul 31Buy20.974,00083,8744,000Aug 02 06:48 PM
COURY ROBERT JDirectorJun 24Option Exercise0.00750,00001,309,835Jun 25 08:04 PM
Gallagher Daniel Martin JrChief Legal OfficerApr 01Option Exercise0.008,515021,133Apr 03 06:00 PM
Campbell PaulSee RemarksMar 04Sale27.5011,533317,14324,137Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002190599Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00830024,493Mar 05 06:15 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,984016,853Mar 05 06:13 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950275,388Mar 05 06:11 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,534098,537Mar 05 06:11 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,218016,567Mar 05 06:09 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420394,503Mar 05 06:06 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.004,02808,258Mar 05 06:33 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.004,028045,845Mar 05 06:30 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.004,56604,566Mar 05 06:27 PM
PARRISH MARK WDirectorMar 02Option Exercise0.004,028041,423Mar 05 06:25 PM
KORMAN HARRYDirectorMar 02Option Exercise0.004,566024,816Mar 05 06:23 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.004,028013,120Mar 05 06:22 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.004,028048,645Mar 05 06:21 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.004,028013,667Mar 05 06:20 PM
Cindrich Robert JDirectorMar 02Option Exercise0.004,028023,107Mar 05 06:16 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001670437Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001,980024,540Mar 05 06:15 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.006,103015,541Mar 05 06:13 PM
Malik RajivPresidentMar 02Option Exercise0.0014,6450269,457Mar 05 06:11 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.006,103095,657Mar 05 06:11 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 02Option Exercise0.007,811012,093Mar 05 06:09 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0022,2120384,223Mar 05 06:06 PM
Malik RajivPresidentFeb 19Option Exercise0.0014,5890584,940Feb 21 06:01 PM
Parks Kenneth ScottChief Financial OfficerFeb 19Option Exercise0.004,837011,550Feb 21 06:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 19Option Exercise0.0025,2870751,359Feb 21 06:00 PM
Campbell PaulSee RemarksFeb 19Option Exercise0.001,216023,157Feb 21 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 19Option Exercise0.007,9430160,520Feb 21 06:00 PM
Malik RajivPresidentFeb 17Option Exercise0.0022,0240579,185Feb 20 06:02 PM
Parks Kenneth ScottChief Financial OfficerFeb 17Option Exercise0.002,14907,733Feb 20 06:00 PM
Campbell PaulSee RemarksFeb 17Option Exercise0.00540022,207Feb 20 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 17Option Exercise0.009,0150156,699Feb 20 05:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 17Option Exercise0.0037,0940742,601Feb 20 05:01 PM